Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) CEO Sells 5,200 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 5,200 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the completion of the transaction, the chief executive officer now directly owns 667,318 shares of the company’s stock, valued at $32,932,143.30. The trade was a 0.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $52.30 on Friday. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The stock has a market capitalization of $3.12 billion, a P/E ratio of -14.53 and a beta of 1.87. The stock has a 50-day simple moving average of $48.84 and a 200-day simple moving average of $46.32.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the previous year, the business earned ($0.75) EPS. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. Analysts predict that Twist Bioscience Co. will post -2.27 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on TWST shares. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Barclays cut their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Scotiabank boosted their target price on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research note on Tuesday. TD Cowen reissued a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Institutional Trading of Twist Bioscience

Institutional investors have recently modified their holdings of the company. ARK Investment Management LLC boosted its holdings in Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after acquiring an additional 237,772 shares during the period. State Street Corp boosted its holdings in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares during the period. Geode Capital Management LLC boosted its holdings in Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after acquiring an additional 26,145 shares during the period. Thrivent Financial for Lutherans purchased a new position in Twist Bioscience in the 3rd quarter worth approximately $43,992,000. Finally, Wellington Management Group LLP boosted its holdings in Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after acquiring an additional 521,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.